Noteworthy distinctions exist among these therapeutic products encompassing variances in costimulatory domain (CD28 vs. 4-1BB) and indications spanning diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). The gene discussed is CD28; the disease is diffuse large B-cell lymphoma.